Related Experiment Video

Updated: Aug 15, 2026

A Protocol for Safe Lithiation Reactions Using Organolithium Reagents
09:45

A Protocol for Safe Lithiation Reactions Using Organolithium Reagents

Published on: November 12, 2016

[Lithium acetate, a useful and well tolerated thyrostatic for selected cases of hyperthyroidism]

F Eigenmann, H Bürgi

    Schweizerische Medizinische Wochenschrift
    |November 25, 1978
    PubMed

    More Related Videos

    Synthesis of Ionic Liquid Based Electrolytes, Assembly of Li-ion Batteries, and Measurements of Performance at High Temperature11:04

    Synthesis of Ionic Liquid Based Electrolytes, Assembly of Li-ion Batteries, and Measurements of Performance at High Temperature

    Published on: December 20, 2016

    Gasless Endoscopic Thyroidectomy via the Trans-Axillary Approach05:10

    Gasless Endoscopic Thyroidectomy via the Trans-Axillary Approach

    Published on: September 15, 2023

    Related Concept Videos

    Acidity of 1-Alkynes02:42

    Acidity of 1-Alkynes


    The acidic strength of hydrocarbons follows the order: Alkynes > Alkenes > Alkanes. The strength of an acid is commonly expressed in units of pKa — the lower the pKa, the stronger the acid. Among the hydrocarbons, terminal alkynes have lower pKa values and are, therefore, more acidic. For example, the pKa values for ethane, ethene, and acetylene are 51, 44, and 25, respectively, as shown here.
    Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

    Direct-Acting Cholinergic Agonists: Therapeutic Uses

    Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

    Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

    Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
    Mania and Antimanic Drugs: Overview01:24

    Mania and Antimanic Drugs: Overview

    Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

    Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
    SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
    Electroconvulsive Therapy01:30

    Electroconvulsive Therapy

    Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...